Clinical Trial Update: A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 study evaluating GFH009 in combination with zanubrutinib for relapsed or refractory diffuse large B-cell lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• GFH009 (GFH009)
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: Genfleet Therapeutics (Shanghai) Inc. | Conditions: Large B-cell Lymphoma | Phase 1, Phase 2 | Status: RECRUITING